Boston Common Asset Management LLC Sells 79,101 Shares of Hologic, Inc. (NASDAQ:HOLX)

Boston Common Asset Management LLC lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 25.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 227,564 shares of the medical equipment provider’s stock after selling 79,101 shares during the quarter. Boston Common Asset Management LLC’s holdings in Hologic were worth $16,405,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Avanza Fonder AB bought a new position in shares of Hologic during the 4th quarter worth approximately $1,861,000. First Community Trust NA increased its stake in shares of Hologic by 2.7% in the fourth quarter. First Community Trust NA now owns 17,165 shares of the medical equipment provider’s stock worth $1,237,000 after acquiring an additional 455 shares during the period. Benson Investment Management Company Inc. acquired a new stake in Hologic during the 4th quarter worth about $4,832,000. Clean Yield Group raised its stake in shares of Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after buying an additional 7,266 shares during the last quarter. Finally, Czech National Bank lifted its holdings in shares of Hologic by 6.4% in the 4th quarter. Czech National Bank now owns 50,362 shares of the medical equipment provider’s stock valued at $3,631,000 after buying an additional 3,046 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of HOLX traded up $0.15 during trading hours on Friday, hitting $70.12. 217,537 shares of the stock were exchanged, compared to its average volume of 2,239,191. The stock’s 50-day moving average price is $75.02 and its two-hundred day moving average price is $78.37. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company has a market cap of $15.91 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.89 earnings per share. Research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several recent research reports. Jefferies Financial Group assumed coverage on Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. UBS Group boosted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Wolfe Research started coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.